Daily CSR https://www.dailycsr.com/ 2026-08-18T01:58:02+02:00 Webzine Maker https://www.dailycsr.com/favicon.ico AsymBio Expands Biologics CDMO with New Shanghai R&D Center 2026-07-27T15:54:00+02:00 https://www.dailycsr.com/AsymBio-Expands-Biologics-CDMO-with-New-Shanghai-R-D-Center_a5993.html https://www.dailycsr.com/photo/art/imagette/97489427-67887309.jpg 2026-07-27T15:52:00+02:00 Debashish Mukherjee AsymBio Expands Biologics CDMO with New Shanghai R&D Center

AsymBio, the biologics-focused Contract Development and Manufacturing Organization (CDMO) under the Asymchem Group (stock codes: 002821.SZ / 6821.HK), has announced the groundbreaking of a new research and development facility at its Fengxian campus in Shanghai. This expansion represents a major milestone in enhancing the company's biologics CDMO capabilities while further establishing the Fengxian site as a key center for research, development, and manufacturing.

Construction commenced in May 2026, with completion and operational launch planned for the second half of 2027. The eight-story building will occupy approximately 2,500 square meters of land and offer nearly 20,000 square meters of total floor space. Designed in accordance with green and low-carbon building principles, the facility will house capabilities for cell line development, upstream and downstream process development, conjugation process development, drug product development, and advanced analytical services.

Situated alongside AsymBio's existing clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs) at the Fengxian campus, the new R&D center will serve as a dedicated innovation hub. Its close integration with manufacturing operations is expected to improve technology transfer, facilitate efficient scale-up, and accelerate the transition from development to commercial production.

The facility will also host the AccPCC (Accelerated PCC Platform), an integrated research and development framework designed to reduce the time required to advance drug candidates from lead identification to preclinical candidate (PCC) selection. Leveraging AI-enabled, end-to-end workflows, the platform brings together early-stage research, Chemistry, Manufacturing and Controls (CMC), nonclinical evaluation, and early clinical translation. It offers comprehensive support in lead optimization, developability assessment, and customized early-stage CMC strategies for biotechnology companies worldwide.

Commenting on the initiative, AsymBio CEO Rui Yang emphasized that successful biologics development depends on early collaboration, integrated scientific and CMC decision-making, and consideration of manufacturability from the beginning of a project. By utilizing the combined R&D expertise available across the Asymchem Group, the AccPCC platform aims to enhance development efficiency, accelerate preclinical candidate selection, and shorten the journey from scientific discovery to clinical application.

The new Fengxian R&D building is expected to strengthen collaboration between research, process scale-up, and manufacturing, enabling clients to minimize development bottlenecks and manage complex biologics programs with greater efficiency and confidence.


]]> Nona Biosciences and Lonza Partner to Advance BBB Technology for CNS Therapies 2026-07-02T16:28:00+02:00 https://www.dailycsr.com/Nona-Biosciences-and-Lonza-Partner-to-Advance-BBB-Technology-for-CNS-Therapies_a5931.html https://www.dailycsr.com/photo/art/imagette/97206688-67725234.jpg 2026-07-02T16:24:00+02:00 Debashish Mukherjee Nona Biosciences and Lonza Partner to Advance BBB Technology for CNS Therapies
Nona Biosciences ("Nona"), a biotechnology company focused on advancing biologics discovery and development through proprietary technology platforms, has announced a strategic partnership with Lonza to create advanced single-domain antibody-based blood-brain barrier (BBB) delivery technologies for the treatment of central nervous system (CNS) disorders.

The collaboration will utilize Nona's proprietary Harbour Mice® fully human HCAb platform to identify and develop next-generation BBB-penetrating technologies based on single-domain antibodies. Recognized for its ability to generate fully human HCAbs and VHH binders with high affinity and favorable developability characteristics, the platform is expected to support the creation of a leading BBB delivery solution. This technology aims to facilitate the transport of a wide range of therapeutic agents into the CNS, opening new possibilities for CNS therapeutics and future licensing opportunities. Lonza will contribute its expertise in protein engineering, along with its GS Gene Expression System® and GlycoConnect® bioconjugation technologies, to optimize selected BBB-crossing candidates and expand their potential applications.

According to the agreement, Nona will receive upfront and option-related payments from Lonza. In addition, both companies will share revenue generated from future licensing arrangements arising from the partnership.

Dr. Jingsong Wang, Chairman of Nona Biosciences, stated that the collaboration reinforces the strength of Nona's technology platform and its strategic commitment to next-generation drug delivery solutions. He noted that Lonza's global presence, regulatory knowledge, and commercial manufacturing capabilities are expected to accelerate the advancement of Nona's BBB-crossing technology. He added that the partnership creates opportunities for licensing, commercialization, and long-term value generation while further strengthening Nona's position in CNS drug delivery and supporting improved patient outcomes.

Dr. Di Hong, Chief Executive Officer of Nona Biosciences, said that the company is pleased to work with Lonza on the development and commercialization of innovative BBB-crossing technologies for CNS diseases. He emphasized that the collaboration highlights the versatility and capabilities of the HCAb Harbour Mice® platform in generating differentiated, fully human single-domain binders capable of overcoming some of the most complex challenges in drug delivery. By combining Nona's platform technologies with Lonza's development and manufacturing expertise, he expressed confidence that the partnership can deliver next-generation BBB solutions and create new therapeutic opportunities for patients affected by severe CNS disorders.

Peter Droc, Head of Licensing at Lonza, stated that acquiring intellectual property rights related to Nona's BBB-crossing technology, together with the ongoing collaboration, will enable customers to more effectively advance promising CNS therapies into clinical and commercial applications. He added that combining the technology with Lonza's flexible CDMO services allows partners to engage at any stage of development—from technology licensing to integrated development and commercial-scale manufacturing—helping to simplify the process and accelerate the delivery of new treatments to patients.

]]>